Singapore · Delayed Price · Currency is SGD iX Biopharma Statistics
Total Valuation
iX Biopharma has a market cap or net worth of SGD 546.66 million. The enterprise value is 537.53 million.
| Market Cap | 546.66M |
| Enterprise Value | 537.53M |
Important Dates
The next estimated earnings date is Tuesday, November 10, 2026.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
iX Biopharma has 1.09 billion shares outstanding. The number of shares has increased by 10.08% in one year.
| Current Share Class | 1.09B |
| Shares Outstanding | 1.09B |
| Shares Change (YoY) | +10.08% |
| Shares Change (QoQ) | +6.39% |
| Owned by Insiders (%) | 36.51% |
| Owned by Institutions (%) | 17.46% |
| Float | 662.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 74.19 |
| PB Ratio | 33.02 |
| P/TBV Ratio | 33.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 72.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.86, with a Debt / Equity ratio of 0.38.
| Current Ratio | 1.86 |
| Quick Ratio | 1.69 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.86 |
Financial Efficiency
Return on equity (ROE) is -101.43% and return on invested capital (ROIC) is -43.52%.
| Return on Equity (ROE) | -101.43% |
| Return on Assets (ROA) | -32.16% |
| Return on Invested Capital (ROIC) | -43.52% |
| Return on Capital Employed (ROCE) | -60.23% |
| Weighted Average Cost of Capital (WACC) | 9.78% |
| Revenue Per Employee | 185,216 |
| Profits Per Employee | -216,027 |
| Employee Count | 37 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 4.18 |
Taxes
In the past 12 months, iX Biopharma has paid 9,000 in taxes.
| Income Tax | 9,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +266.14% in the last 52 weeks. The beta is 1.01, so iX Biopharma's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +266.14% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.37 |
| Relative Strength Index (RSI) | 39.60 |
| Average Volume (20 Days) | 11,652,885 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, iX Biopharma had revenue of SGD 6.85 million and -7.99 million in losses. Loss per share was -0.01.
| Revenue | 6.85M |
| Gross Profit | 2.43M |
| Operating Income | -9.56M |
| Pretax Income | -7.98M |
| Net Income | -7.99M |
| EBITDA | -9.19M |
| EBIT | -9.56M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 14.93 million in cash and 5.80 million in debt, with a net cash position of 9.13 million or 0.01 per share.
| Cash & Cash Equivalents | 14.93M |
| Total Debt | 5.80M |
| Net Cash | 9.13M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 15.40M |
| Book Value Per Share | 0.01 |
| Working Capital | 8.61M |
Cash Flow
In the last 12 months, operating cash flow was -7.51 million and capital expenditures -115,000, giving a free cash flow of -7.62 million.
| Operating Cash Flow | -7.51M |
| Capital Expenditures | -115,000 |
| Depreciation & Amortization | 371,000 |
| Net Borrowing | -1.17M |
| Free Cash Flow | -7.62M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 35.52%, with operating and profit margins of -139.52% and -116.64%.
| Gross Margin | 35.52% |
| Operating Margin | -139.52% |
| Pretax Margin | -116.50% |
| Profit Margin | -116.64% |
| EBITDA Margin | -134.10% |
| EBIT Margin | -139.52% |
| FCF Margin | n/a |
Dividends & Yields
iX Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.08% |
| Shareholder Yield | -10.08% |
| Earnings Yield | -1.66% |
| FCF Yield | -1.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for iX Biopharma is 1.09, which is 117.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1.09 |
| Price Target Difference | 117.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 205.21% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
iX Biopharma has an Altman Z-Score of 3.32 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.32 |
| Piotroski F-Score | 4 |